Brief: Eagle Pharmaceuticals Receives 180 Days Of Marketing Exclusivity For Recently Approved Vasopressin
29/12/2021 16:26
Dec 29 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS RECEIVES 180 DAYS OF MARKETING
EXCLUSIVITY
FOR RECENTLY APPROVED VASOPRESSIN
Source text for Eikon: urn:newsml:reuters.com:*:nBw4d3tqca
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq